Summary & Overview
HCPCS J1575: Immune Globulin with Hyaluronidase (HyQvia), 100 mg
HCPCS Level II code J1575 denotes administration of immune globulin combined with hyaluronidase (brand: HyQvia), billed per 100 mg of immune globulin. This code is used for subcutaneous delivery of immunoglobulin therapy facilitated by hyaluronidase to enable larger-volume dosing. Nationally, J1575 is relevant for immunodeficiency and autoimmune disease management where immunoglobulin replacement or immunomodulation is indicated and where subcutaneous administration is preferred or necessary.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. The publication provides a concise review of coverage and billing context across major commercial and federal payers, including typical sites of service and coding considerations that affect claims processing and site selection.
Readers will learn the clinical context of J1575, expected settings for administration, and the types of benchmarks and policy updates commonly associated with this class of biologic therapy. The summary highlights where to find documentation essentials, common billing modifiers (listed separately), and what to expect in payer policies and prior authorization practices. Data not available in the input is noted where applicable.
Billing Code Overview
HCPCS Level II code J1575 represents an injection of immune globulin combined with hyaluronidase (HyQvia), billed per 100 mg of immune globulin. This code describes a biologic immunoglobulin product formulated with hyaluronidase to facilitate subcutaneous administration of larger volumes.
Service type: Therapeutic infusion/injection of immune globulin with hyaluronidase
Typical site of service: Outpatient infusion center or clinic; may also be administered in a physician office or home health setting depending on payer coverage and clinical plan of care.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult with primary or secondary immunodeficiency receiving subcutaneous immune globulin facilitated by hyaluronidase (hyqvia) for replacement therapy. The patient arrives for a scheduled infusion at an infusion center, hospital outpatient infusion clinic, or may receive training for home administration. A nurse verifies identity, reviews allergies and current medications, confirms baseline vital signs, and reviews prior infusion tolerance. The J1575 product is supplied in vial or premixed form and dosed based on weight and immunoglobulin requirements (reported per 100 mg units). The infusion is prepared using aseptic technique, hyaluronidase is included to allow larger-volume subcutaneous administration, and infusion pump settings are programmed. During infusion, the nurse monitors for local site reactions, systemic hypersensitivity, anaphylaxis, or volume overload; vital signs are recorded periodically. Post-infusion, the patient is observed for a standard monitoring period, discharge instructions are provided, and infusion details (units administered, lot numbers, route subcutaneous with hyaluronidase) are documented in the medical record for billing and product tracking.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
11 | Active/Concurrent Care |